Gene-Therapy Maker Sarepta Tanks After Patient Death
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Patient dies following muscular dystrophy gene therapy, Sarepta reports
The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the ...
GEN - Genetic Engineering and Biotechnology News4d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.
BioPharma Dive5d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Fierce Pharma5d
Sarepta reports one death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
Reuters5d
Sarepta says teen died after its gene therapy treatment
The patient underwent treatment in December with Sarepta's therapy, called Elevidys, the company told Reuters in an emailed statement. Elevidys is the only FDA-approved gene therapy for Duchenne ...
Yahoo Finance3d
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech ...